全文获取类型
收费全文 | 17325篇 |
免费 | 1469篇 |
国内免费 | 704篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 174篇 |
妇产科学 | 156篇 |
基础医学 | 923篇 |
口腔科学 | 599篇 |
临床医学 | 1505篇 |
内科学 | 2675篇 |
皮肤病学 | 399篇 |
神经病学 | 506篇 |
特种医学 | 665篇 |
外国民族医学 | 1篇 |
外科学 | 1567篇 |
综合类 | 1976篇 |
现状与发展 | 1篇 |
预防医学 | 800篇 |
眼科学 | 152篇 |
药学 | 5035篇 |
4篇 | |
中国医学 | 768篇 |
肿瘤学 | 1524篇 |
出版年
2023年 | 235篇 |
2022年 | 307篇 |
2021年 | 575篇 |
2020年 | 600篇 |
2019年 | 619篇 |
2018年 | 639篇 |
2017年 | 631篇 |
2016年 | 661篇 |
2015年 | 727篇 |
2014年 | 1043篇 |
2013年 | 1754篇 |
2012年 | 1030篇 |
2011年 | 1130篇 |
2010年 | 835篇 |
2009年 | 792篇 |
2008年 | 827篇 |
2007年 | 832篇 |
2006年 | 678篇 |
2005年 | 689篇 |
2004年 | 552篇 |
2003年 | 520篇 |
2002年 | 437篇 |
2001年 | 380篇 |
2000年 | 312篇 |
1999年 | 245篇 |
1998年 | 193篇 |
1997年 | 229篇 |
1996年 | 161篇 |
1995年 | 172篇 |
1994年 | 144篇 |
1993年 | 156篇 |
1992年 | 136篇 |
1991年 | 130篇 |
1990年 | 109篇 |
1989年 | 104篇 |
1988年 | 106篇 |
1987年 | 103篇 |
1986年 | 81篇 |
1985年 | 83篇 |
1984年 | 85篇 |
1983年 | 62篇 |
1982年 | 60篇 |
1981年 | 47篇 |
1980年 | 49篇 |
1979年 | 45篇 |
1978年 | 41篇 |
1977年 | 28篇 |
1976年 | 33篇 |
1975年 | 18篇 |
1974年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
The consumption of dietary supplements (DSs) is rising among children. Lately the composition of such products has come under considerable criticism. Sweetening agents (SA) were identified and quantified in dietary supplements, which take the form of lollipops (lollipop supplements) using HPLC and the calorific value of the analysed products was determined using a caloric bomb. The purpose of the study was to evaluate: (i) content of SA in lollipop supplements, (ii) energetic value of the daily dose of lollipop supplement vs the average energy requirement (AR) for children aged 3–12 and (iii) potential impact that the sweetening agents, found in lollipop supplements, may have on children’s health. The analysis of the energy values of the supplements’ daily doses shows a significant impact of such dose of supplement on the energy balance of the daily diet amounting to 12.74 % of a 7-year-old female child’s AR for energy (kcal/day). 相似文献
32.
《Clinical genitourinary cancer》2020,18(1):1-10
Many therapeutic options are now available for men with metastatic castration-resistant prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted therapies (AATTs), immunotherapy, chemotherapy, and radioisotope therapies. No clear consensus has been reached for the optimal sequencing of treatments for patients with mCRPC, and few well-validated molecular markers exist to guide the treatment decisions for individual patients. The androgen receptor splice variant 7 (AR-V7), a splice variant of the androgen receptor mRNA resulting in the truncation of the ligand-binding domain, has emerged as a biomarker for resistance to AATT. AR-V7 expression in circulating tumor cells has been associated with poor outcomes in patients treated with second- and third-line AATTs. Clinically validated assays are now commercially available for the AR-V7 biomarker. In the present review of the current literature, we have summarized the biology of resistance to AATT, with a focus on the AR-V7; and the clinical studies that have validated AR-V7 expression as a strong independent predictor of a lack of clinical benefit from AATTs. Existing evidence has indicated that patients with AR-V7–positive mCRPC will have better outcomes if treated with taxane chemotherapy regimens rather than additional AATTs. 相似文献
33.
《Surgery for obesity and related diseases》2022,18(6):762-771
BackgroundNew antidiabetic agents (sodium-glucose cotransporter-2 inhibitor [SGLT2i] and glucagon-like peptide-1 receptor agonist [GLP-1RA]) and metabolic surgery have protective effects on metabolic syndromes.ObjectivesTo compare the changes of metabolic parameters and costs among patients with obesity and type 2 diabetes undergoing metabolic surgery and initiating new antidiabetic agents over 12 months.SettingHong Kong Hospital Authority database from 2006–2017.MethodsThis is a population-wide retrospective cohort study consisting of 2616 patients (1810 SGLT2i, 528 GLP-1RA, 278 metabolic surgery). Inverse probability treatment weighting of propensity score was applied to balance baseline covariates of patients with obesity and type 2 diabetes who underwent metabolic surgery, or initiated SGLT2i or GLP-1RA. Metabolic parameters and direct medical costs were measured and compared from baseline to 12 months in metabolic surgery, SGLT2i, and GLP-1RA groups.ResultsPatients in all 3 groups had improved metabolic parameters over a 12-month period. Patients with metabolic surgery achieved significantly better outcomes in BMI (?5.39, ?.56, ?.40 kg/m2, P < .001), % total weight loss (15.16%, 1.34%, 1.63%, P < .001), systolic (?2.21, ?.59, 1.28 mm Hg, P < .001) and diastolic (?1.16, .50, ?.13 mm Hg, P < .001) blood pressure, HbA1c (?1.80%, ?.77%, ?.80%, P < .001), triglycerides (?.64, ?.11, ?.09 mmol/L, P < .001), and estimated glomerular filtration rate (3.08, ?1.37, ?.41 mL/min/1.73m2, P < .001) after 12 months compared with patients with SGLT2i and GLP1-RA. Although the metabolic surgery group incurred the greatest direct medical costs (US$33,551, US$10,945, US$10,627, P < .001), largely due to the surgery itself and related hospitalization, the total monthly direct medical expenditure of metabolic surgery group became lower than that of SGLT2i and GLP-1RA groups at 7 months.ConclusionBeneficial weight loss and metabolic outcomes at 12 months were observed in all 3 groups, among which the metabolic surgery group showed the most remarkable effects but incurred the greatest medical costs. However, studies with a longer follow-up period are warranted to show long-term outcomes. 相似文献
34.
狼毒Euphorbiae Ebracteolatae Radix为大戟科(Euphorbiaceae)植物狼毒大戟Euphorbia fischeriana或月腺大戟E.ebracteolata的干燥根,是一种广泛应用,具有广阔开发前景的中药材。狼毒含有多种生物活性成分,其中二萜类化合物是最为重要的一个部分,主要包括松香烷型、巴豆烷型、海松烷型、玫瑰烷型、西松烷型、巨大戟烷型、贝壳杉烷型、阿替斯烷型8种类型,此外还有少量二萜二聚体及其他类型的二萜类化合物。狼毒二萜类化学成分具有显著的抗肿瘤、抗炎、抗菌、抗病毒等药理作用。对狼毒二萜类化学成分及其药理作用进行综述,以期为更好地开发狼毒资源及其临床应用提供参考。 相似文献
35.
36.
Multiple sclerosis(MS)is an inflammatory demyelinating disease of the central nervous system.The disability caused by inflammatory demyelination clinically dominates the early stages of relapsing-remitting MS and is reversible.Once there is considerable loss of axons,MS patients enter a secondary progressive stage.Disease-modifying drugs currently in use for MS suppress the immune system and reduce relapse rates but are not effective in the progressive stage.Various animal models of MS(mostly mouse and rat)have been established and proved useful in studying the disease process and response to therapy.The experimental autoimmune encephalomyelitis animal studies reviewed here showed that a chronic progressive disease can be induced by immunization with appropriate amounts of myelin oligodendrocyte glycoprotein together with mycobacterium tuberculosis and pertussis toxin in Freund's adjuvant.The clinical manifestations of autoimmune encephalomyelitis disease were prevented or reduced by treatment with certain pharmacological agents given prior to,at,or after peak disease,and the agents had protective effects as shown by inhibiting demyelination and damage to neurons,axons and oligodendrocytes.In the cuprizone-induced toxicity animal studies,the pharmacological agents tested were able to promote remyelination and increase the number of oligodendrocytes when administered therapeutically or prophylactically.A monoclonal IgM antibody protected axons in the spinal cord and preserved motor function in animals inoculated with Theiler's murine encephalomyelitis virus.In all these studies the pharmacological agents were administered singly.A combination therapy may be more effective,especially using agents that target neuroinflammation and neurodegeneration,as they may exert synergistic actions. 相似文献
37.
ABSTRACT
Introduction
Despite recent advances in the treatment of adult acute myelogenous leukemia (AML), the overall outcome remains dismal especially in high-risk AML patients, including the elderly and the relapsed/refractory populations. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. 相似文献38.
Jay A. Graham Julia Torabi Maria Ajaimy Enver Akalin Luz E. Liriano Yorg Azzi Cindy Pynadath Stuart M. Greenstein Doctor Y. Goldstein Amy S. Fox Jeffery M. Weiss Tia P. Powell John F. Reinus Milan M. Kinkhabwala Juan P. Rocca 《Clinical transplantation》2020,34(4):e13833
The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R−). Thirty D+/R− patients received DAA treatment. Sustained virologic response (SVR12) was defined as an undetectable viral load in 12 weeks after treatment. An age-matched cohort of uninfected donor and recipient pairs (D−/R−) transplanted during same time period was used for comparison. The median day of viral detection was postoperative day (POD) 2. The detection of viremia in D+/R− patients was 100%. The initial median viral load was 531 copies/μL (range: 10-1 × 108 copies/μL) with a median peak viral load of 3.4 × 105 copies/μL (range: 804-1.0 × 108 copies/μL). DAAs were initiated on median POD 9 (range: 5-41 days). All 30 patients had confirmed SVR12. During a median follow-up of 10 months, patient and graft survival was 100%, and acute rejection was 6.6% with no major adverse events related to DAA treatment. Delayed graft function was significantly decreased in D+/R− patients as compared to the age-matched cohort (27% vs 60%; P = .01). D+/R− transplantation offers patients an alternative strategy to increase access. 相似文献
39.
目的分析北京市2012-2018年抗结核药物的使用情况与变化趋势,为北京市进一步规范及修改结核药物的使用策略提供数据参考。方法对2012-2018年北京市46家医院J04A类抗结核药物的销售金额、用药频度(Defined daily doses,DDDs)、药品限定日费用(Defined daily cost,DDC)等指标进行统计分析与评价。采用SPSS 22.0线性回归分析,判断变化趋势。结果 2012-2018年抗结核药销售金额逐年上升,而销售量在2016年到达高峰后缓慢下降;2012年和2018年相比抗结核的药物种类构成变动不大,各类药物销售金额构成变化较大;抗结核药物以一线、口服为主,二线、注射为辅,且二线用药的销售金额、DDDs和注射用药的销售金额有上升的趋势(P均<0.05);抗生素销售单价以注射类经济负担最重,且2018年较2012年,大部分种类药物都有不同程度的价格增长。结论抗结核药物的DDDs在2012-2018年间保持平稳,但大部分种类抗结核药物的DDC均出现上升趋势,患者经济负担增大,且抗结核药物使用存在用药集中的现象,带来的耐药风险不容忽视。 相似文献
40.